CoChat

Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions

Open access
Guimaraes, Thales Antonio Cabral de, Georgiou, Michalis, Bainbridge, James W B, Michaelides, Michel · 2021 · British Journal of Ophthalmology
Cited by 91

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in the developed world. Antivascular endothelial growth factor therapy has transformed the management and outcome of neovascular AMD (nAMD), although the need for repeated intravitreal injections—even lifelong—and the related complications, high drug costs, frequent clinic visits and repeated imaging have resulted in an enormous burden both to healthcare systems and patients. The application of gene therapy approaches for sustained delivery of a range of antiangiogenic proteins has the promise of helping to address these aforementioned challenges. A number of early phase clinical trials of gene therapy in nAMD have provided encouraging results, with many more ongoing or anticipated. There remain significant areas of controversy, including regarding the optimal treatment targets, routes of administration and potential safety concerns. In this review we aim to provide an update of the current status of gene therapy for nAMD and briefly discuss future prospects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bjophthalmol-2020-316195

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 57

  1. 10.1136/bjophthalmol-2017-310368 · DOI
  2. Keel, 2017, Prevalence of age-related macular degeneration in Australia: the Australian National eye health survey, JAMA Ophthalmol, 135, 1242, 10.1001/jamaophthalmol.2017.4182 · DOI
  3. Wilde, 2017, Prevalence of age-related macular degeneration in an elderly UK Caucasian population-The Bridlington eye assessment project: a cross-sectional study, Eye, 31, 1042, 10.1038/eye.2017.30 · DOI
  4. Wong, 2014, Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis, Lancet Glob Health, 2, e106, 10.1016/S2214-109X(13)70145-1 · DOI · Paper page
  5. 10.1136/bjophthalmol-2019-314422 · DOI · Paper page
  6. 10.1016/j.ophtha.2012.10.036 · DOI · Paper page
  7. Lai, 2015, Current choice of treatments for neovascular AMD, Expert Rev Clin Pharmacol, 8, 135, 10.1586/17512433.2015.990379 · DOI
  8. 10.1016/j.ophtha.2013.01.057 · DOI
  9. 10.1016/j.ajo.2012.06.031 · DOI
  10. Hussain, 2017, Treatment Burden in Neovascular AMD:Visual Acuity Outcomes are Associated With Anti-VEGF Injection Frequency, Ophthalmic Surg Lasers Imaging Retina, 48, 780, 10.3928/23258160-20170928-01 · DOI
  11. 10.1016/j.ophtha.2012.11.048 · DOI · Paper page
  12. 10.1016/j.ophtha.2016.03.003 · DOI · Paper page
  13. Rosen, 2002, Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers, Cancer Control, 9, 36, 10.1177/107327480200902S05 · DOI · Paper page
  14. 10.1167/iovs.02-1092 · DOI · Paper page
  15. 10.1097/BCR.0b013e3181c7ed82 · DOI · Paper page
  16. 10.1042/CS20040370 · DOI · Paper page
  17. 10.1210/er.2003-0027 · DOI · Paper page
  18. 10.1016/S0002-9440(10)64525-7 · DOI · Paper page
  19. 10.1038/nrc2505 · DOI · Paper page
  20. Dehghanian, 2014, New insights into VEGF-A alternative splicing: key regulatory switching in the pathological process, Avicenna J Med Biotechnol, 6, 192
  21. 10.1093/nar/gkt539 · DOI · Paper page
  22. 10.1016/j.it.2004.05.003 · DOI · Paper page
  23. 10.1016/0006-291X(92)90483-2 · DOI · Paper page
  24. 10.1073/pnas.88.20.9267 · DOI · Paper page
  25. 10.1126/science.1312256 · DOI · Paper page
  26. 10.1093/bmb/ldy005 · DOI · Paper page
  27. 10.1128/JVI.76.2.791-801.2002 · DOI · Paper page
  28. 10.1007/978-1-4614-3209-8_86 · DOI
  29. 10.1089/hum.2017.172 · DOI
  30. 10.2174/1566523054065039 · DOI · Paper page
  31. Li, 2008, Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential, Mol Vis, 14, 1760
  32. Bruewer, 2013, Evaluation of lateral spread of transgene expression following subretinal AAV-mediated gene delivery in dogs, PLoS One, 8, 10.1371/journal.pone.0060218 · DOI · Paper page
  33. 10.1038/mt.2008.41 · DOI · Paper page
  34. Reid, 2017, Improvement of photoreceptor targeting via intravitreal delivery in mouse and human retina using combinatory rAAV2 capsid mutant vectors, Invest Ophthalmol Vis Sci, 58, 6429, 10.1167/iovs.17-22281 · DOI
  35. Jüttner, 2019, Targeting neuronal and glial cell types with synthetic promoter AAVs in mice, non-human primates and humans, Nat Neurosci, 22, 1345, 10.1038/s41593-019-0431-2 · DOI · Paper page
  36. Ali, 1998, Adeno-Associated virus gene transfer to mouse retina, Hum Gene Ther, 9, 81, 10.1089/hum.1998.9.1-81 · DOI
  37. Habot-Wilner, 2019, Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach, Acta Ophthalmol, 97, 460, 10.1111/aos.14042 · DOI · Paper page
  38. 10.1016/j.jcrs.2007.03.051 · DOI · Paper page
  39. Jung, 2019, Targeting drug delivery within the suprachoroidal space, Drug Discov Today, 24, 1654, 10.1016/j.drudis.2019.03.027 · DOI
  40. 10.1159/000336045 · DOI
  41. Yeh, 2019, Suprachoroidal injection of triamcinolone acetonide, CLS-TA, for macular edema due to noninfectious uveitis: a randomized, phase 2 study (DOGWOOD), Retina, 39, 1880, 10.1097/IAE.0000000000002279 · DOI
  42. Rasmussen, 2001, Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD), Hum Gene Ther, 12, 2029
  43. 10.1089/hum.2006.17.167 · DOI · Paper page
  44. 10.1073/pnas.90.22.10705 · DOI · Paper page
  45. 10.1089/hum.2012.008 · DOI · Paper page
  46. Campochiaro, 2017, Lentiviral vector gene transfer of Endostatin/Angiostatin for macular degeneration (GEM) study, Hum Gene Ther, 28, 99, 10.1089/hum.2016.117 · DOI · Paper page
  47. Kumar-Singh, 2019, The role of complement membrane attack complex in dry and wet AMD - From hypothesis to clinical trials, Exp Eye Res, 184, 266, 10.1016/j.exer.2019.05.006 · DOI
  48. 10.1101/gad.1653708 · DOI · Paper page
  49. Hussain, 2017, Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration, Expert Opin Emerg Drugs, 22, 235, 10.1080/14728214.2017.1362390 · DOI
  50. 10.1038/nrm2639 · DOI · Paper page
  51. 10.1167/iovs.14-13897 · DOI
  52. 10.1126/sciadv.aau6732 · DOI
  53. Xia, 2008, Inhibition of retinal neovascularization by siRNA targeting VEGF(165), Mol Vis, 14, 1965
  54. Garba, 2010, Bevasiranib for the treatment of wet, age-related macular degeneration, Ophthalmol Eye Dis, 2, OED.S4878, 10.4137/OED.S4878 · DOI · Paper page
  55. 10.1016/j.ajo.2010.02.006 · DOI · Paper page
  56. 10.1002/jgm.2678 · DOI · Paper page
  57. 10.1002/jgm.2623 · DOI

Cited by

See all 91

Metadata

Authors
Guimaraes, T. A. C. D., Georgiou, M., Bainbridge, J. W. B., & Michaelides, M.
Venue
British Journal of Ophthalmology
Publisher
BMJ
Published
2020-04-08
Volume
105
Issue
2
Pages
151-157
ISSN
  • 0007-1161 (ISSN-L)
  • 1468-2079
OpenAlex
W3015569704
Cited by
91
References
25
FWCI
9.58
Type
journal article
Language
en
Open access
hybrid
Funders
  • National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology (NA)
  • Foundation Fighting Blindness (NA)
  • Retina UK (NA)
  • Wellcome Trust (099173/Z/12/Z)
  • Fight for Sight (NA)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions. https://app.cochat.ai/papers/10.1136/bjophthalmol-2020-316195
The paper
Guimaraes, T. A. C. D., Georgiou, M., Bainbridge, J. W. B., & Michaelides, M. (2021). Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2020-316195

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.